KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Acquisitions & DivestmentsChange in CashDeferred TaxesDepreciation & Amortization (CF)DivestmentsDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pfizer (PFE) Change in Acquisitions & Divestments (2016 - 2025)

Historic Change in Acquisitions & Divestments for Pfizer (PFE) over the last 16 years, with Q3 2025 value amounting to $2.7 billion.

  • Pfizer's Change in Acquisitions & Divestments rose 403.04% to $2.7 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $15.9 billion, marking a year-over-year decrease of 3799.44%. This contributed to the annual value of $4.1 billion for FY2024, which is 8948.66% down from last year.
  • According to the latest figures from Q3 2025, Pfizer's Change in Acquisitions & Divestments is $2.7 billion, which was up 403.04% from $6.5 billion recorded in Q2 2025.
  • In the past 5 years, Pfizer's Change in Acquisitions & Divestments registered a high of $35.1 billion during Q4 2022, and its lowest value of $658.0 million during Q1 2024.
  • Moreover, its 5-year median value for Change in Acquisitions & Divestments was $5.8 billion (2021), whereas its average is $8.5 billion.
  • As far as peak fluctuations go, Pfizer's Change in Acquisitions & Divestments crashed by 8971.88% in 2024, and later soared by 52096.77% in 2025.
  • Pfizer's Change in Acquisitions & Divestments (Quarter) stood at $15.9 billion in 2021, then surged by 121.34% to $35.1 billion in 2022, then crashed by 39.45% to $21.2 billion in 2023, then plummeted by 87.62% to $2.6 billion in 2024, then rose by 4.03% to $2.7 billion in 2025.
  • Its Change in Acquisitions & Divestments was $2.7 billion in Q3 2025, compared to $6.5 billion in Q2 2025 and $4.0 billion in Q1 2025.